首页> 外文期刊>The Psychiatric Clinics of North America >Understanding and treating 'first-episode' schizophrenia.
【24h】

Understanding and treating 'first-episode' schizophrenia.

机译:了解和治疗“首发”精神分裂症。

获取原文
获取原文并翻译 | 示例
           

摘要

"First-episode schizophrenia" is a clinical and research term that often is used to emphasize the special issues that arise when working with this patient population. The notion that schizophrenia has an inexorable downhill course or is a deteriorating illness is being challenged by more sophisticated understanding of what happens before the initial episode and new understanding of the interactions between biologic vulnerabilities and specific environmental risk during adolescence and early adulthood, such as marijuana use. While the incidence rate of "first-episode" will make this a relatively small percentage of a usual clinical caseload, it is a critically important time for the future course of the illness. The hope is that proper management during this critical period will favorably influence the long-term trajectory of outcome for this individual patient. A growing body of evidence suggests that certain approaches and interventions are more helpful than others, such as understanding of the overwhelming nature of the experience to patients and families, aiming to achieve a full and broad pharmacologic response to initial antipsychotic therapy, while also being on the lookout for vulnerability and extreme sensitivity to side effects, and to anticipate a high likelihood of premature medication discontinuation. Clinicians and treatment services should try to identify "first-episode" patients in time to be able to anticipate and address these issues.
机译:“首发精神分裂症”是一个临床和研究术语,通常用来强调与该患者群体打交道时出现的特殊问题。对精神分裂症的病情发展势不可挡或病情恶化的观念正受到对初次发作之前发生的事情的更深入了解以及对青春期和成年早期的生物脆弱性与特定环境风险之间的相互作用的新理解(例如大麻)的挑战。用。尽管“首发”的发病率将使之仅占一般临床病例的一小部分,但这对于疾病的未来发展至关重要。希望在此关键时期进行适当的治疗将有利于影响该患者的长期结局。越来越多的证据表明,某些方法和干预措施比其他方法和干预措施更有帮助,例如了解患者和家属的压倒性本质,旨在实现对初始抗精神病药物治疗的全面而广泛的药理反应,同时还在继续寻找脆弱性和对副作用的极度敏感性,并预期过早停药的可能性很高。临床医生和治疗服务机构应设法及时发现“首发”患者,以便能够预期和解决这些问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号